KAKEN PHARMACEUTICAL CO.,LTD.
Meeting of FY2024 Financial Results May 13, 2025
Event Summary [Company Name] KAKEN PHARMACEUTICAL CO.,LTD. [Company ID] 4521-QCODE [Event Language] JPN [Event Type] Earnings Announcement [Event Name] Meeting of FY2024 Financial Results [Fiscal Period] FY2024 Annual [Date] May 13, 2025 [Number of Pages] 52 [Time] 13:00 - 14:00(Total: 60 minutes, Presentation: 40 minutes, Q&A: 20 minutes)
Hiroyuki Horiuchi President and Representative Director
Masashi Suzudo Managing Director
Masahiro Matsuura Director
Mitsuru Watanuki Director, Chief Officer of R&D Division Yasuhiro Umeda Director
Tomoyuki Koseki Corporate Officer, Chief Officer of Marketing
& Sales Division
Presentation Nonaka: It is now time, so we will begin the meeting of FY2024 financial results of KAKEN PHARMACEUTICAL CO.,LTD. Thank you very much for taking time out of your busy schedule to attend our meeting today.My name is Nonaka from the Corporate Communications Department, and I will be your moderator today. Thank you very much for your cooperation.
If the transmission is interrupted or the video is frozen while you are watching, please wait a few minutes and try accessing the site again. We will post the video on our website at a later date, so if there are any problems with the video or audio today, please check our website then.
The script of this briefing will be made available at a later date for a more in-depth understanding of the contents of the briefing. It will include statements and presentations made during the briefing, so we ask for your understanding and cooperation in this matter.
First of all, we would like to introduce the attendees representing the Company. In attendance today are Mr. Hiroyuki Horiuchi, President and Representative Director. Mr. Masashi Suzudo, Managing Director. Directors Masahiro Matsuura, Mitsuru Watanuki and Yasuhiro Umeda. And Mr. Tomoyuki Koseki, Corporate Officer, Chief Officer of Marketing & Sales Division. They are the six officers here with us today.
There will be time for questions and answers after all presentations are completed.
We have some reminders for today's briefing.
Today's explanation will follow the presentation materials posted on our website. Please note that the information in the presentation materials has been deemed reasonable by the Company based on information currently available and may differ significantly from these forward-looking statements. These materials contain information on pharmaceutical products, but such content is not intended to be an advertisement or medical advice.
Now, Mr. Horiuchi will explain.
Horiuchi: I am Horiuchi, president of the Company. Thank you for taking time out of your busy schedule today to listen to our financial results presentation. We would also like to express our sincere appreciation for your continued support of our company's efforts.This is today's agenda.
First of all, I will explain our consolidated financial results for the fiscal year ended March 31, 2025, and our forecast for the fiscal year ending March 31, 2026. Next, our managing director, Mr. Suzudo, will review the Long-Term Business Plan 2031 and provide updates on our actions to implement management that is conscious of cost of capital and stock price. Finally, Mr. Watanuki, director and general manager of R&D division, will give updates on research and development, or R&D.
All right, I will now explain our consolidated financial results for the fiscal year ended March 31, 2025. This slide shows our consolidated profit and loss results.
In the fiscal year ended March 31, 2025, both sales and profit increased. Details will be explained on the next slide.